Eli Lilly’s limited October 2024 research-only agreement with Peptron, which granted non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release but no commercial licensing rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or full licensing deal has materialized despite the 14-month research window, while Lilly separately partnered with Camurus in June 2026 on the competing FluidCrystal platform for long-acting incretins. Recent uncertainty around the collaboration triggered Peptron stock volatility in July 2026, and Lilly’s shift toward oral obesity candidates has further reduced momentum for a near-term SmartDepot commercial agreement before the October 7 resolution date.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% шанс
$11,264 Обс.
$11,264 Обс.
Oct 7, 2026
13% шанс
$11,264 Обс.
$11,264 Обс.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s limited October 2024 research-only agreement with Peptron, which granted non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release but no commercial licensing rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or full licensing deal has materialized despite the 14-month research window, while Lilly separately partnered with Camurus in June 2026 on the competing FluidCrystal platform for long-acting incretins. Recent uncertainty around the collaboration triggered Peptron stock volatility in July 2026, and Lilly’s shift toward oral obesity candidates has further reduced momentum for a near-term SmartDepot commercial agreement before the October 7 resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Ринок відкрито: May 5, 2026, 8:02 PM ET
Обсяг
$11,264Дата завершення
Oct 7, 2026Ринок відкрито
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s limited October 2024 research-only agreement with Peptron, which granted non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release but no commercial licensing rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or full licensing deal has materialized despite the 14-month research window, while Lilly separately partnered with Camurus in June 2026 on the competing FluidCrystal platform for long-acting incretins. Recent uncertainty around the collaboration triggered Peptron stock volatility in July 2026, and Lilly’s shift toward oral obesity candidates has further reduced momentum for a near-term SmartDepot commercial agreement before the October 7 resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Обсяг
$11,264Дата завершення
Oct 7, 2026Ринок відкрито
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s limited October 2024 research-only agreement with Peptron, which granted non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release but no commercial licensing rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or full licensing deal has materialized despite the 14-month research window, while Lilly separately partnered with Camurus in June 2026 on the competing FluidCrystal platform for long-acting incretins. Recent uncertainty around the collaboration triggered Peptron stock volatility in July 2026, and Lilly’s shift toward oral obesity candidates has further reduced momentum for a near-term SmartDepot commercial agreement before the October 7 resolution date.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання